A Magnetic-Responsive Biomimetic Nanosystem Coated with Glioma Stem Cell Membranes Effectively Targets and Eliminates Malignant Gliomas
Source abstract
Abstract
Glioblastoma multiforme (GBM) is among the most challenging malignant brain tumors, making the development of new treatment strategies highly necessary. Glioma stem cells (GSCs) markedly contribute to drug resistance, radiation resistance, and tumor recurrence in GBM. The therapeutic potential of nanomaterials targeting GSCs in GBM urgently needs to be explored. A magnetic-responsive biomimetic nanosystem (FDPM), coated with glioma stem cell membranes (CMs), was designed for the targeted eradication of GSCs as well as their associated tumor cells. Identified nanobodies were extensively characterized with various assays. The application tests on nanomaterials were conducted in vitro and in vivo. The tumor-suppressive effects of the nanosystem were evaluated in vitro and in vivo. FDPM can be artificially directed under magnetic guidance while inheriting various biological functions from CM. Upon intravenous injection, FDPM was drawn to the tumor site by magnetic attraction, where it could cross the blood–brain barrier aided by CM. Its homologous targeting ability originates from active proteins on CM, enabling it to specifically target GSCs and related tumor cells. The encapsulated doxorubicin (DOX) within the nanoparticle then destroyed these tumor cells. FDPM demonstrated excellent biocompatibility and tumor-targeting efficiency, effectively targeting malignant gliomas initiated by GSCs. FDPM significantly reduced tumor cells, inhibited tumor growth, and notably extended the survival of glioma-bearing nude mice. The findings position FDPM as a promising nanoplatform to target GSCs and related tumor cells for improving the therapeutic effect of glioma.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Department of Neurosurgery, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng, Yancheng, Jiangsu 224001, P.R. China.
Department of Neurology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Institute of Pain Medicine and Special Environmental Medicine, Nantong University, Jiangsu 226019, P.R. China.
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China.
Center for Advanced Low-Dimension Materials, State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201600, P.R. China.
School of Pharmacy, Key Laboratory of Smart Drug Delivery (Ministry of Education), Fudan University, Shanghai 201203, P.R. China.
Funding
National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province
References (41)
Show source-provided references
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.10.3322/caac.21763 ↗
2. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.10.1056/NEJMoa1308573 ↗
3. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21(Suppl 5):v1–v100.10.1093/neuonc/noz150 ↗
4. Kauer TM, Figueiredo J-L, Hingtgen S, Shah K. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. 2011;15(2):197–204.10.1038/nn.3019 ↗
5. 10.1038/s41565-020-00843-710.1038/s41565-020-00843-7 ↗
6. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68(15):6043–6048.10.1158/0008-5472.CAN-08-1079 ↗
7. 10.1101/gad.324301.11910.1101/gad.324301.119 ↗
8. 10.1093/neuonc/nox17010.1093/neuonc/nox170 ↗
9. Cui Q, Yang S, Ye P, Tian E, Sun G, Zhou J, Sun G, Liu X, Chen C, Murai K, et al. Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nat Commun. 2016;7:10637.10.1038/ncomms10637 ↗
10. Dirks PB. Cancer: Stem cells and brain tumours. Nature. 2006;444(7120):687–688.10.1038/444687a ↗
11. Seton-Rogers S. Glioblastoma: Cancer stem cell knockout. Nat Rev Cancer. 2014;14(7):452–453.10.1038/nrc3771 ↗
12. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760.10.1038/nature05236 ↗
13. Osuka S, Zhu D, Zhang Z, Li C, Stackhouse CT, Sampetrean O, Olson JJ, Gillespie GY, Saya H, Willey CD, et al. N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. J Clin Invest. 2021;131(6):e136098.10.1172/JCI136098 ↗
14. 10.1016/j.ccr.2009.03.01810.1016/j.ccr.2009.03.018 ↗
15. 10.1016/j.drup.2018.03.00310.1016/j.drup.2018.03.003 ↗
16. Xie Q, Flavahan WA, Bao S, Rich J. The tailless root of glioma: Cancer stem cells. Cell Stem Cell. 2014;15(2):114–116.10.1016/j.stem.2014.07.004 ↗
17. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.10.1038/nature03128 ↗
18. 10.1016/j.stem.2014.04.00710.1016/j.stem.2014.04.007 ↗
19. Galdieri L, Jash A, Malkova O, Mao DD, DeSouza P, Chu YE, Salter A, Campian JL, Naegle KM, Brennan CW, et al. Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight. 2021;6(4):e128456.
20. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
21. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
22. Lu G, Wang X, Li F, Wang S, Zhao J, Wang J, Liu J, Lyu C, Ye P, Tan H, et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat Commun. 2022;13(1):4214.10.1038/s41467-022-31799-y ↗
23. 10.1002/adma.20160217310.1002/adma.201602173 ↗
24. Wu S, Lu L, Zhou J, Ran D, Wang S, Xu Q, Xu W, Wang J, Liu Y, Xie C, et al. All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals. J Control Release. 2022;345:685–695.10.1016/j.jconrel.2022.03.047 ↗
25. Chai Z, Ran D, Lu L, Zhan C, Ruan H, Hu X, Xie C, Jiang K, Li J, Zhou J, et al. Ligand-modified cell membrane enables the targeted delivery of drug nanocrystals to glioma. ACS Nano. 2019;13(5):5591–5601.10.1021/acsnano.9b00661 ↗
26. Jia Y, Wang X, Hu D, Wang P, Liu Q, Zhang X, Jiang J, Liu X, Sheng Z, Liu B, et al. Phototheranostics: Active targeting of orthotopic glioma using biomimetic proteolipid nanoparticles. ACS Nano. 2019;13(1):386–398.10.1021/acsnano.8b06556 ↗
27. Xie X, Jiang K, Li B, Hou S, Tang H, Shao B, Ping Y, Zhang Q. A small-molecule self-assembled nanodrug for combination therapy of photothermal-differentiation-chemotherapy of breast cancer stem cells. Biomaterials. 2022;286: Article 121598.10.1016/j.biomaterials.2022.121598 ↗
28. 10.1021/acs.nanolett.6b0278610.1021/acs.nanolett.6b02786 ↗
29. 10.1038/nprot.2008.5510.1038/nprot.2008.55 ↗
30. Han X-X, Cai C, Yu L-M, Wang M, Hu D-Y, Ren J, Zhang M-H, Zhu L-Y, Zhang W-H, Huang W, et al. A fast and efficient approach to obtaining high-purity glioma stem cell culture. Front Genet. 2021;12: Article 639858.10.3389/fgene.2021.639858 ↗
31. Zhang H, Guan S, Wei T, Wang T, Zhang J, You Y, Wang Z, Dai Z. Homotypic membrane-enhanced blood-brain barrier crossing and glioblastoma targeting for precise surgical resection and photothermal therapy. J Am Chem Soc. 2023;145(10):5930–5940.10.1021/jacs.2c13701 ↗
32. 10.1021/acsnano.9b0879810.1021/acsnano.9b08798 ↗
33. Lai Y-H, Su C-Y, Cheng H-W, Chu C-Y, Jeng L-B, Chiang C-S, Shyu W-C, Chen S-Y. Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat Commun. 2023;14(1):285.10.1038/s41467-023-35935-0 ↗
34. Zhang Z, Guan J, Jiang Z, Yang Y, Liu J, Hua W, Mao Y, Li C, Lu W, Qian J, et al. Brain-targeted drug delivery by manipulating protein corona functions. Nat Commun. 2019;10(1):3561.10.1038/s41467-019-11593-z ↗
35. 10.1007/s11064-008-9723-810.1007/s11064-008-9723-8 ↗
36. Pinpointing cancer stem cells in oligodendroglioma. Cancer Discov. 2017;7(1):6.10.1158/2159-8290.CD-NB2016-149 ↗
37. 10.1016/j.ccell.2020.04.00110.1016/j.ccell.2020.04.001 ↗
38. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824–828.10.1038/nature09557 ↗
39. 10.1038/s41593-018-0285-z10.1038/s41593-018-0285-z ↗
40. Wang Z, Liang P, He X, Wu B, Liu Q, Xu Z, Wu H, Liu Z, Qian Y, Wang S, et al. Etoposide loaded layered double hydroxide nanoparticles reversing chemoresistance and eradicating human glioma stem cells in vitro and in vivo. Nanoscale. 2018;10(27):13106–13121.10.1039/C8NR02708K ↗
41. Jing G, Li Y, Sun F, Liu Q, du A, Wang H, Niu J, Lu J, Qian Y, Wang S. Near-infrared light-activatable upconversion nanoparticle/curcumin hybrid nanodrug: A potent strategy to induce the differentiation and elimination of glioma stem cells. Adv Compos Hybrid Mater. 2024;7:82.10.1007/s42114-024-00886-7 ↗